NCT04077463 2026-03-17
Chrysalis-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Clinical Trials
4 trialsNCT02609776 2026-01-16
CHRYSALIS
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06632236 2025-04-25
5G-EMERALD
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT06816992 2025-03-20
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
Phase 1 Recruiting